TABLE 3.
dPCRgyrA-T83I assay results for clinical samples with a significant amplification signal
| Patient no. (n = 20) | No. of respiratory samples (n = 34) |
Sampling daya | % of T83I mutants | |
|---|---|---|---|---|
| FQ | No FQ | |||
| 4–20 | 19 | 7 | 0 or uninterpretableb | |
| 1 | 1 | 0 | 0 | |
| 1 | 10 | 0 | ||
| 1 | 15 | 0 | ||
| 1 | 22 | 0.13 | ||
| 2 | 1 | 1 | 0 | |
| 1 | 2 | 0.43 | ||
| 1 | 5 | 1.13 | ||
| 3 | 1 | 5 | 0.83 | |
a
Sampling day is given according to the day of legionellosis diagnosis.
b
Three samples with mutant sequences in proportions inferior to dPCRgyrA-T83I assay sensitivity (0.1%) and/or background noise (0.43 FAM copies/μl).